2022 January
(Jan 19, 2022) | By Heather McKenzie Two-year-old biotech company Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world. Enveda’s home base in Boulder, Colorado – where many ponder the wonders of the Rocky Mountains every day – could not be more fitting. In June
Continue Reading(Jan 11, 2022) California-based Dren Bio and Pfizer have partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.
Continue Reading(Jan 10, 2022) Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants the Germany-based pharma giant access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies. The companies plan to harness the power of the CRISPR technology across five preselected in vivo indications. While the companies did not disclose all
Continue Reading(Jan 07, 2022) Vancouver, Wash.-based Absci Corporation inked a research pact with Merck. Under the deal, Absci will leverage its Bionic Protein non-standard amino acid technology and its artificial intelligence-powered integrated Drug Creation Platform to create enzymes to meet Merck’s biomanufacturing applications. Under the terms of the agreement, Absci is eligible for up to $610 million in upfront
Continue Reading